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INTRODUCTION 
Peritoneal dialysis is one available mode of therapy in patients 
with renal failure. The technique of peritoneal dialysis has advan-
tages over alternative modes of therapy, such as hemodialysis, in that 
it is less expensive and can be performed by the patients themselves 
1 2 
at home after a brief training period. * A major problem complicat-
ing the use of peritoneal dialysis is the frequent occurrence of 
peritonitis caused by a number of gram-positive and gram-negative 
bacteria.3'4 
Cefoxitin is a semi-synthetic, broad-spectrum antibiotic with 
demonstrated in vitro activity against a wide range of gram-positive 
and gram-negative organisms (see Appendix A). The manufacturer states 
that organisms are considered susceptible to cefoxitin when the 
minimum inhibitory concentration is 16 mcg/mi or less. Cefoxitin, a 
cephamycin C analogue produced by Streptomyces lactamdurans, is al-
most entirely excreted unchanged in the urine. As cefoxitin is active 
against many of the organisms involved in bacterial peritonitis, it is 
important to determine the disposition and kinetic parameters of 
cefoxitin in peritoneal dialysis to aid in establishing appropriate 
therapeutic regimens for patients undergoing peritoneal dialysis and 
who develop a bacterial peritonitis. 
This study was designed, therefore, to evaluate; 
1. The pharmacokinetics of cefoxitin in patients during peritoneal 
dialysis. 
2 
2. The total amount of drug removed by peritoneal dialysis. 
3. The ratio of serum to dialysate (peritoneal fluid) concentrations 
of cefoxitin following intravenous and intraperitoneal adminis-
tration of cefoxitin. 
4. The serum concentrations of cefoxitin attained in patients, in 
the presence and absence of peritonitis, and a comparison with 
the minimum inhibitory concentrations cited for common etiologic 
organisms. 
5. The dialysate concentrations of cefoxitin that are attained and 
maintained during the course of cefoxitin therapy in patients, in 
the presence or absence of peritonitis, and a comparison of 
levels with the minimum inhibitory concentrations cited for common 
etiologic organisms. 
6. The methodology used to determine its use as a model for further 
study of other antibiotics used in patients requiring peritoneal 
dialysis. 
MATERIALS AND METHODS 
Patient Population 
Patients included in the study were hospitalized at the University 
of Utah Hospital. Only patients admitted for peritoneal catheter 
placement requiring prophylactic cephalosporin antibiotic therapy and 
patients undergoing continuous or intermittent peritoneal dialysis 
therapy requiring antibiotic treatment for infections caused by docu-
mented or suspected organisms sensitive to cefoxitin were eligible for 
inclusion in the study. Patients were excluded if they were less than 
18 years of age; if they had a "history or suspected history of a 
3 
"hypersensitivity reaction to cephalosporin or cephamycin antibiotics or 
an anaphylactic reaction to a penicillin antibiotic; or if they were 
receiving other concomitantly administered antibiotics. 
Treatment 
After an appropriate patient was identified and informed written 
consent obtained (see Appendix B) , the patient was treated with either 
intravenous or intraperitoneal cefoxitin. 
Seven patients received peritoneal dialysis therapy for a total 
of eight therapeutic trials. One patient (patient 1) underwent two 
trials, once with intravenous cefoxitin and once with intraperitoneal 
cefoxitin. In the five trials with intravenous cefoxitin, patients 
received a 2 gram dose one hour prior to surgery. In the three trials 
with intraperitoneal cefoxitin, two patients received 500 mg/1 and 
one patient (patient 7) received 250 mg/1 of cefoxitin in the dialy-
sate fluid. (The lower dose of cefoxitin for patient 7 was due to 
the investigators' efforts to determine an acceptable concentration 
for the study without compromising patient therapy). All patients, 
with the exception of patient 7, were without peritonitis on entering 
the study; patient 7 had developed peritonitis prior to initiation of 
the study. 
Sample Collection for Antibiotic Assay 
A sterile indwelling intravenous catheter (heparin lock) was in-
serted into a superficial vein of the forearm opposite the one used 
for infusions; blood samples were obtained through this catheter. Ten 
units of heparin sodium were instilled into the catheter to maintain 
its patency between sampling intervals. Thus, it was necessary to 
discard the first 1-2 mis of blood to clear the heparin from the 
catheter prior to obtaining the 1 ml sample for assay. Sampling times 
were variable for each patient and are noted in Tables II-IX. 
During dialysis, dialysate fluid samples were drawn while fluid 
was draining from the patient. The total volume of dialysate was 
determined every 24 hours and an aliquot taken for assay to allow a 
quantitation of the total amount of drug removed by dialysis. In 
patients with urine output, all urine was collected during the study 
and an aliquot saved to be assayed for cefoxitin. 
Blood samples were placed in an evacuated blood collection tube 
and centrifuged for five minutes at 1000 g and the serum transferred 
by pipette into an empty, prelabeled blood collection tube. Serum, 
dialysate, and urine samples were then frozen at -70°C. This proce-
dure was completed within 60 minutes of sample collection. The 
cefoxitin concentrations in each sample were determined by a micro-
biological assay procedure using a modified method described by Bennett 
et al (see Appendix C). 
Pharmacokinetic Analysis 
Data were analyzed using a one-compartment open model for linear 
kinetics. The data in the elimination phase were subject to linear 
regression analysis using the method of least squares, as determined 
using a programmable calculator (Texas Instruments, TI-59). The elimi-
nation rate constant, elimination half-life, apparent volume of dis-
tribution, and total body clearance were all determined according to 
accepted methods (see Appendix D). 
Statistical Analysis 
The data collected during the study were subjected to Student's 
t-test for independent samples comparing the volumes of distribution, 
elimination half-lives, and total body clearances on and off peritoneal 
dialysis. 
RESULTS 
A total of eight trials in seven patients were included in this 
study. One patient (patient 7) entered the study with peritonitis; 
the remaining six patients were uninfected. In five trials, intra-
venously administered cefoxitin was studied; and in three trials, in-
traperitoneal cefoxitin was studied. The patients ranged in age from 
18 to 65 years with a mean age of 44 and a median of 40 years (see 
Table 1). All patients had chronic renal failure requiring peritoneal 
dialysis therapy. Individual patient serum cefoxitin concentrations 
after receiving either intravenous or intraperitoneal cefoxitin are 
presented in Tables II to IX. The pharmacokinetic parameters on and 
off peritoneal dialysis for patients without peritonitis are summa-
rized in Tables X and XI. The mean (+ standard deviation) elimination 
half-life after intravenous cefoxitin during peritoneal dialysis was 
13.01 ±5.55 hours while the mean elimination half-life in patients 
off peritoneal dialysis after intravenous or intraperitoneal cefoxitin 
was 16.71 ± 7.06 hours. The mean volume of distribution, determined 
after intravenous cefoxitin, during peritoneal dialysis was 0.19 ± 0.07 
1/kg with a mean volume of distribution off peritoneal dialysis of 
0.26 ± 0.07 1/kg. The mean body clearance on peritoneal dialysis was 
18.2 ± 11.6 ml/iiin (0.32 ± 0,25 ml/kg/min) and 9.11 ± 5 ml/min (0.11 ± 
6 
0,08 ml/kg/min) off peritoneal dialysis. Calculations were based on 
actual body weight. A mean 10.57 percent of an intravenous cefoxitin 
dose was removed by dialysis (see Table XII), while a mean 19.93 per-
cent of an intravenous cefoxitin dose was removed via the urine during 
the study period (see Table XIII). Three of the five intravenous 
cefoxitin patients produced urine; thus allowing the percent of ad-
ministered dose excreted via the urine in these patients to be calcu-
lated. Figures 1-8 present graphical representations of the serum 
cefoxitin concentrations over time for each patient for the time in-
tervals during and post-peritoneal dialysis. A mean time of 3.25 
hours was required to reach a serum cefoxitin level of 16 meg/ml 
(therapeutic breakpoint) from intraperitoneal cefoxitin administration 
in patients without peritonitis. The one patient with peritonitis 
achieved a serum cefoxitin level of 16 meg/ml after 2.5 hours after 
250 mg/1 of intraperitoneal cefoxitin while the other patients re-
ceived 500 mg/1 of intraperitoneal cefoxitin. In addition, the high-
est serum concentration noted after intraperitoneal cefoxitin occurred 
in this infected patient. 
The mean cefoxitin dialysate concentration after intravenous 
cefoxitin administration was 9 ± 7 mcg/ml and exceeded 16 mcg/ml in 
only 3 of 17 exchanges. The data on the penetration of cefoxitin from 
the serum to dialysate fluid are presented in Table XIV. Data from 
additional patients with peritonitis would be required for adequate 
comparison and analysis. 
Statistical analysis of the mean volumes of distribution, total 
body clearances, and elimination half-lives both on and off peritoneal 
dialysis indicate that the differences observed are not statistically 
significant (Student's t-test, p >0.05). 
DISCUSSION 
The half-life of cefoxitin is prolonged in patients with renal 
disease. The mean elimination half-life noted in this study was 16.71 
hours with a range of 9.3 to 31.5 hours in patients during the post-
peritoneal dialysis period, The half-life of cefoxitin in subjects 
with normal renal function is approximately 40 minutes and increases 
to 23.5 ± 9.0 hours in patients with glomerular filtration rates less 
5 
than 3 ml/min. The shorter mean cefoxitin half-life in this study 
is most probably due to urinary elimination of cefoxitin. 
Vlasses et al studied the pharmacokinetics of intravenous and 
intraperitoneal cefoxitin in four male patients, without peritonitis, 
undergoing chronic intermittent peritoneal dialysis.^ The mean half-
life was 19.8 ± 9.5; the mean volume of distribution was 0.26 + 0.8 
1/kg and the total body clearance was approximately 18.6 ml/min. 
Vlasses also reported a mean cefoxitin dialysate concentration of 7.8 
±3.8 mcg/ml in which concentrations greater than 16 mcg/ml (thera-
peutic breakpoint) were achieved in only 2 of 43 exchanges. These 
observations are comparable to those generated by this study, 
In this study, cefoxitin clearance was not significantly in-
creased by peritoneal dialysis. This observation was also noted in a 
study of cefoxitin pharmacokinetics in patients undergoing continuous 
ambulatory peritoneal dialysis.^ No correlations between urine output 
time on peritoneal dialysis, and the amount of cefoxitin removed via 
either urine or dialysate were noted in the current study. 
Examination of the data collected indicates that in patients with-
out peritonitis, intravenously administered cefoxitin does not reliably 
achieve therapeutic concentrations in the dialysate. The alternative 
of intraperitoneal cefoxitin does appear to yield therapeutic serum 
levels even in the absence of peritonitis. However, a lag time of 
3.25 hours and 2.5 hours was observed to reach the therapeutic break-
point of 16 mcg/ml of uninfected and infected patients, respectively. 
Thus, an intravenous loading dose of cefoxitin might be advisable in 
situations when rapid achievement of adequate serum levels is desired. 
However, a number of infecting organisms have minimum inhibitory 
concentration values for cefoxitin below 16 mcg/ml. 
The comparable pharmacokinetic parameters for cefoxitin calculated 
in this study and those of Vlasses, as well as the consistent data for 
patient 1 during different hospital admissions and by different routes 
of cefoxitin administration, indicate the feasibility of utilizing this 
study's methodology in further study of this and other antibiotics. 
Data from the patient with peritonitis demonstrated high cefoxitin 
levels on half the intraperitoneal dose administered to uninfected 
patients. Further study in patients with peritonitis will be necessary 
to determine the therapeutic and pharmacokinetic parameters required to 
evaluate intravenous and intraperitoneal routes of cefoxitin 
administration. 
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Figure 1. Graph of data collected from patient 1 after intravenous 
cefoxitin. Solid circles: patient on peritoneal dialysis 
( r2 = 0.999). Squares; patient off peritoneal dialysis 
(x- = 0.979). 
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Figure 2. Graph of data collected - from patient 2 after intravenous cefoxitin. 
Solid circles: patient on peritoneal dialysis (r^  = 0.993). 
Squares: patient off peritoneal dialysis (r^  = 0.636). 
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Figure 3. Graph of data collected from patient 3 after 
intravenous cefoxitin. Solid circles: patient 
on peritoneal dialysis (r2 = 0.992). Squares: 
patient off peritoneal dialysis (r2 = 0.864); 
data collected prior to catheter placement. 
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Figure 4. Graph of data collected from patient 4 after 
intravenous cefoxitin. Solid circles: patient 
on peritoneal dialysis (r^  = 0.994). Squares: 
patient off peritoneal dialysis. 
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Figure 5. Graph of data collected from patient 5 after 
intravenous cefoxitin. Solid circles: patient 
on peritoneal dialysis (r2 = 0.878). Squares: 
patient off peritoneal dialysis (r2 = 0.998). 
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Figure 6. Graph of data collected from patient 6 after intraperitoneal cefoxitin. 
Solid circles: patient on peritoneal dialysis. Squares: patient off 
peritoneal dialysis (r2 - 0.996); serum levels higher due to longer 
final dwell time. 
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Graph of data collected from patient 7 after 
intraperitoneal cefoxitin. Solid circles: 
patient on peritoneal dialysis- Patient 7 
entered the study with peritonitis and re-
ceived 250 mg/1 intraperitoneal cefoxitin. 
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Figure 8. Graph of data collection from patient 1 after 
intraperitoneal cefoxitin. Solid circles: 
patient on peritoneal dialysis. Square: 
patient off peritoneal dialysis (r2 = 0.997). 
TABLES 
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1 F 18 54.7 49.9 162.6 
2 M 31 66.1 65.3 170.2 
3 M 65 68.4 75.7 172.7 
4 M 40 70.7 66.2 175.3 
5 M 65 70.7 64.4 175.3 
6 F 25 55.9 102.5 163.8 
7 M 64 73 68.7 177.8 
IBW = ideal body weight calculated according to the following 
equation: 
Female: 45.5 kg/5 ft. of height + 2.3 kg/inch over 5 ft. 
Male: 50 kg/5 ft. of height + 2.3 kg/inch over 5 ft. 
+ABW = actual body weight 
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Table II. Serum cefoxitin concentrations in patient 1 after 
A 
intravenous cefoxitin 
Time Serum Concentration 
(Hrs. post-dose) (mcg/ml) 
During Peritoneal Dialysis 
6 172 
8 .25 144 
11.25 114 
30 2 6 . 2 
Post-Peritoneal Dialysis 
33 .5 32 
36.5 22.1 
39.25 23 
56 8 . 8 
59.5 8 . 1 
Patient 1 received a total of 6 grams of cefoxitin over 
an 18 hour period prior to serum sample collection 
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Table III. Serum cefoxitin concentrations in patient 2 after 2 gm 
intravenous cefoxitin 
Time Serum Concentration 
(Hrs. post-dose) (mcg/ml) 












Table IV. Serum cefoxitin concentrations in patient 3 after 2 gm 
intravenous cefoxitin 
Time Serum Concentration 
(Hrs. post-dose) (mcg/ml) 











Cefoxitin kinetics off peritoneal dialysis determined in this 
patient prior to catheter placement. A second 2 gram dose was 
then administered prior to peritoneal dialysis. The estimated 
serum cefoxitin concentration prior to this dose was 13,4 mcg/ml. 
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Table V. Serum cefoxitin concentrations in patient 4 after 2 pi 














Table VI. Serum cefoxitin concentrations in patient 5 after 2 gm 
intravenous cefoxitin 
Time Serum Concentration 
(Hrs. post-dose) (mcg/ml) 








Table VII. Serum cefoxitin concentrations after 500 mg/1 intra-
peritoneal cefoxitin in patient 6 
Time Concentration 
(Hrs. post-dose) (mcg/ml) 















Table VIII. Serum cefoxitin concentrations after 500 mg/1 intra-
peritoneal cefoxitin in patient 1 
Time Concentration 
(Hrs. post-dose) (mcg/ml) 














Table IX. Serum cefoxitin, concentrations after 250 mg/1 intra-
peritoneal cefoxitin in patient 7 
Time Concentration 
(Hrs. post-dose) (mcg/ml) 
During Peritoneal Dialysis 
2.75 16.6 
12 .5 85 .5 
17 .75 147 
Post-Peritoneal Dialysis 
No data available as patient was terminated from further 
study due to the addition of other concomitantly admin-
istered antibiotics. Patient 7 entered the study with 
peritonitis. 
Table X. Pharmacokinetic parameters off dialysis in uninfected patients given IV and IP cefoxitin 
Volume of 
Distribution 
k i el 
1 AUC 
Total Body Clearance 
Patient (1/kg) (hr L) (hrs) (mg.hr/1) (ml/min) or (ml/kg/min) 
1 0 . 1 4 0 .052 13 .33 3773 5 . 2 4 0.11 
la+ ID§ 0 . 0 5 9 11 .83 1292.8 5 . 94 0 . 12 
2 0 . 2 8 0 . 0 3 6 19 .31 837 .2 9 .53 0 . 0 1 
3 0 . 2 8 0 . 0 2 2 31.5 6758.4 3 .74 0 . 05 
4 0 . 3 5 0 . 0 5 8 11.95 434 .8 18 .6 0 . 2 8 
5 0 . 2 3 0 .035 19 .8 3382 .4 5 . 6 2 0 . 0 9 




0 . 2 6 0 .046 1 6 . 7 1 2539.9 8 . 1 1 0.11 
± 0 . 0 7 ± 0 .017 ± 7 . 0 6 ± 2085.6 ± 5 ± 0 . 0 8 
Refer to Appendix D for definition and calculation of parameters 
+ Patient 1 received both IV and IP cefoxitin; la represents data off dialysis after IP cefoxitin 
^ SD = standard deviation 
g 
ID = insufficient data 
Table XI. Pharmacokinetic parameters during peritoneal dialysis in uninfected patients * after IV cefoxitin 
Volume of 
Distribution 
k . el S AUC Total Body Clearance 
Patient (1/kR) (hr (hrs) (mft-hr/1) (ml/min) or (ml/kg/min) 
1 0.12 0.078 8.88 3615.5 9.22 0.19 
2 0.24 0.061 11.36 1800 18.5 0.28 
3 0.13 0.044 15.75 2124.6 15.69 0.21 
4 0.29 0.103 6.73 835.2 39.9 0.81 
5 0.15 0.031 22.35 4338.6 7.68 0.12 
Mean 
± SD 
0.19 0.063 13.01 2542.8 18.2 0.32 
± 0.07 ± 0.025 ± 5.55 ± 1266.3 ± 11.6 ± 0.25 
* 
Refer to Appendix D for definition and calculation of parameters 




















1 64,37 40.25 673.71 11.23 
2 35.85 43 135 6.75 
3 59.65 45.25 444-34 22.22 
4 17.26 51 81.56 4.08 
5 8.15 20.75 144.75 7.24 
Patient 1 was given a total of 6 grams of cefoxitin. 
All others received 2 grams of cefoxitin. 
+ Refer to Table XI? for dialysate cefoxitin concentration data. 
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1 1590 0.55 874.5 41.08 14.57 
* 
la 12 9 9» 2 X. 1.07 1390.16 31.33 -
2 - Anuric - - -
3 - Anuric _ - -
4 369.57 2.35 868.5 25.37 43.43 
5 959.92 0.26 249.58 44.5 12.48 
* 
6 474.90 2.53 1201.5 48.58 -
7*+ 773.31 0.26 201.06 5.75 -
These patients received intraperitoneal cefoxitin 
4. 
Patient 7 entered the study with peritonitis and received only 
250 mg/1 IP cefoxitin 
Table XI?. Cefoxitin penetration into dialysate fluid 
32 
Serum Dialysate Dialysate 
Time Concentration Concentration Serum 
(Hrs. post-dose) (mcg/ml) (mcg/ml) Ratio 
Patient 1 
2 130 18.8 0.145 
5 96.5 5.2 0.054 
18,75 156.4 24.9 0.159 
23 114 13.5 0.118 
41.5 26.2 7.1 0.271 
Mean fraction penetration into dialysate: 0.149 
Patient 2 
5.25 66.3 7.3 0.11 
18 38.8 4.9 0.126 
19.75 29.99 <4 
Mean fraction penetration into dialysate: 0.118 
Patient 3 
1.75 62 19.5 0.315 
17 36.6 15.1 0.413 
26.75 23.8 8.4 0.353 
41.25 11.9 5.8 0.487 
45.75 9.3 3.9 0.419 
Mean fraction penetration into dialysate: 0.397 
33 
Table XIV. (continued) 
5 50 4.8 0.096 
18.25 11.4 2.7 0.237 
24.5 6.67 0.7 0.105 
26.5 6.2 1.1 0.177 
Mean fraction penetration into dialysate; 0.154 
Patient 5 
Patient 5 developed an outflow obstruction and data 
were not evaluable 
APPENDIX A 
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Cefoxitin Minimum Inhibitory Concentration (MIC) 
8 9 10 
Data for Selected Organisms ' ' 
Mean MIC Range 
Organism (mcg/ml) (mcg/ml) 
Staphylococcus aureus 1 . 5 <0.5 - >64 
Staphylococcus epidermidis 1.5 <0.5 - >64 
Streptococcus faecalis 100 25 - 100 
Streptococcus spp. 8 2 - 3 2 
Escherichia coli 6 1 - >64 
Klebsiella pneumoniae 3 • 2 - >64 
Proteus mirabilis 3 2 - 8 
Proteus, indole-positive 8 2 - >64 
Serratia marcescens 25 2 - >64 
Neisseria gonorrhoeae 0.25 0.25 - 10 
Interobacter aerogenes 3 8 - >64 
Enterobacter cloacae 3 4 - >64 
Acinetobacter 25 1 - >64 
Pseudomonas aeruginosa >100 >64 
Bacteroides fragilis 16 8 - 6 4 




X voluntarily agree to participate as a subject in a research study 
to evaluate the use of the antibiotic, cefoxitin, in 20 patients like 
myself, who receive peritoneal dialysis, I understand that cefoxitin 
is an antibiotic which will be given to treat or attempt to prevent an 
infection which I might have. Cefoxitin is known to be an effective 
antibiotic used to kill the organism which are most likely to cause my 
infection. I understand that I will receive either 500 mg/1 of cefoxi-
tin through my dialysate fluid during dialysis treatment, or 2 grams of 
cefoxitin into my vein for two doses. This will in no way affect my 
normal therapy except for the antibiotic given. Another antibiotic 
which is very similar to cefoxitin would normally be given. 
Blood samples will be drawn from me during my treatment. A heparin 
lock which is a tube that will be placed into my vein will be used to 
take the blood samples when possible. The total amount of blood taken 
will be approximately 1% ounces (3 tablespoons). When possible, my 
urine will be collected to measure the amount of antibiotic I excrete. 
Samples of the dialysate fluid going into and coming out of my body 
will be measured to determine the amount of cefoxitin in the fluid. I 
understand that special sampling sites have been placed into the dialy-
sis tubing which should minimize contaminating the tubing with bacteria 
when the samples are taken. 
1 understand that when blood samples are taken there may be some dis-
comfort and that it may also be uncomfortable when the heparin lock 
(tube) is placed into my vein. All other risks from the antibiotic 
(allergic reaction, rash, inflammation of the vein) are the same as the 
antibiotics I would normally receive. I understand that the chance of 
an infection is slightly increased when samples are drawn but all pre-
cautions will be taken to minimize this. 
The benefits from my participation In this study will be more knowledge 
concerning the use of cefoxitin in subjects like myself who require 
peritoneal dialysis. The antibiotic concentrations in my blood, urine 
and dialysis fluid will be measured closely at no charge to myself. 
I participate in this study voluntarily and understand that I may re-
fuse to participate without any penalty or change in my normal therapy. 
I may withdraw from the study at any time I wish. 1 have had an oppor-
tunity to ask questions regarding this study. 
Medical treatment or compensation for physical injury: In the event you 
sustain physical injury resulting from the research project in which you 
are participating, the University of Utah will provide you, without 
charge, emergency and temporary medical treatment not otherwise covered 
by Insurance. Furthermore, if your injuries are caused by negligent acts 
or omissions of University employees acting in the course and scope of 
their employment, the University may be liable, subject to limitations 
38 
prescribed by law, for additional medical costs and other damages you 
sustain. If you believe that you have suffered a physical injury as a 
result of participation in this research program, please contact the 
Office of Research Administration, Phone Ho. 581-6903. 
(Date) (Name) (Signature) 
(Witness) (Investigators Signature) 
If the patient is unable to sign, complete the following: 
I hereby approve participation of 
in this study. 
(Signature of approving person) 
(Legal position of approving person) 
APPENDIX C 
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ANTIBIOTIC ASSAY USING LARGE SQUARE PLATES 
FOR CEFOXITIN 
Seed Organism 
Staph, aureus B2786G 
Medium Used 
Brain Heart Infusion agar (manufactured by Difco) 
Assay Plates 
Large 14 x 14 inch square glass plates with lids 
Antibiotic Standards 
All standards for serum samples were diluted in single donor 
serum (known donor) 
All standards for dialysate and urine samples were diluted in 
normal saline 
To 250 ml of the media is added 0.75 ml of seed organism broth suspen-
sion. Swirl and pour into one large square glass plate allowing the 
plate to rest on a flat surface until the agar solidifies. 
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ANTIBIOTIC ASSAY USING THE LARGE PLATES 
(Square 14 x 14" Glass Plates)11 
Grow seed organisms overnight if not. available. 
Prepare 250 ml of the appropriate antibiotic media early in the 
morning or prepare the media the night before and remelt the media 
by placing briefly in a boiling water bath. 
While the media is melting or autoclaving, read results of anti-
biotic assay prepared the day before if applicable. 
Once the media is melted or autoclaved, place in a 56°C water bath. 
Pre-warm the 14 x 14" glass plate in a 35°C incubator. 
Start separating, organizing, inactivating aminoglycosides if 
required and diluting patient serum samples. 
Organize the cefoxitin standards and dilute them if necessary. 
Seed the cooled 250 ml agar (cooled to about 50°C) with the ap-
propriate amount and organism to be used. Swirl and pour into the 
glass plate that has been transferred to a flat surface at room 
temperature. 
In the approximately 30 minutes while the agar plate is solidifying, 
place serum samples and controls on the discs that have been set out 
on a large screen. Use tape on the screen to identify each sample. 
Prepare a template using a large sheet of mylar (this can be rubbed 
clean and re-used). Use an Eppendorf pipetter (0.02 ml), a variable 
Eppendorf pipetter, or similar pipette system to deliver 0.02 ml to 
each disc. Prepare five discs each for every patient serum sample 
and antibiotic standard. Discs to be used are blank Penicillin 
Assay discs one-fourth inch in diameter. In order to equalize the 
results, the discs are allowed to dry for approximately 30 minutes 
or the time required for the agar to solidify (the time for discs 
to dry is dependent on local humidity conditions). 
10. Prepare a paper template indicating where the discs are to be 
placed. It is advisable to line up the mylar template with the 
paper template. 
11. Using a slight amount of pressure, place the discs on the agar 
surface. 
12. Incubate the plate in a level position overnight at 35°C. 
13. Read zones of inhibition the following day and average the five 
zones for each serum sample and the five zones for each standard. 




DEFINITION AND CALCULATION OF 
12 
PHARMACOKINETIC PARAMETERS 
The data collected in this study were evaluated using a one-
compartment open model. The following is a brief discussion of the 
definitions and equations used to define the pharmacokinetic para-
meters of cefoxitin in this study. 
A one-compartment open model assumes instantaneous distribution 
into the body tissues. As no definite distribution phase could be 
identified, the model was considered appropriate to evaluate the study 
data. The following is a list of definitions and equations for the 
kinetic parameters calculated: 
1. k , = elimination rate constant of first order kinetics. This 
el 
is calculated from the negative slope of the line during 
the elimination phase. 
2. tl = half-life of the drug. 
0.693 
* = kel 
3. V d = apparent volume of distribution. 
V, = • : — . rTO where Qbn Is the amount of drug in the d k , AUC 0 e X 
body at time zero, 
4. CI.,, = total body clearance = the clearance of the hypothetical 
plasma volume of drug per unit time due to excretion via 
kidney, liver, etc., and metabolism. 
C L = k . x V = 
B el d A U C 
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Doctor of Pharmacy (Pharm.D.) 
College of Pharmacy 
University of Utah 
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University of Utah 
College of Pharmacy - 1978-1980 
Salt Lake City, UT 
San Francisco State University - Jan. 1978-May 1978 
San Francisco, CA 
Fulfilled partial degree requirements for Master of Arts in 
Microbiology 
Bachelor of Arts in Microbiology 
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EDUCATIONAL BACKGROUND (Continued) 
Bachelor of Arts in Biochemistry 
San Francisco State University - Dec. 1977 
San Francisco, CA 
Associate of Arts in' Science 
City College of San Francisco - June 1975 
San Francisco, CA 
Clinical Rotations 
Adult Medicine 18 weeks 
General Surgery 6 weeks 
Critical Care (Shock-Trauma ICU) 6 weeks 
Perinatology (OB/GYN) 6 weeks 
Psychiatry 6 weeks 
Ambulatory Pediatrics/Geriatrics 6 weeks 
General Pediatrics 6 weeks 
Hyperalimentation 3 weeks 
Drug Information 6 weeks 
Adult Nephrology 3 weeks 
Rheumatology 6 weeks 
Pain Management 3 weeks 
Oncology 3 weeks 
Infectious Disease 6 weeks 
Poison Control Center 80 hours 
Hospital Pharmacy Management 3 weeks 
PROFESSIONAL EXPERIENCE 
Residency in Clinical Pharmacy - June 1982 
Department of Pharmacy Practice 
Responsibilities: teaching (didactic and clerkship); clinical 
rotations; cardiac arrest team participation 
night call; clinical seminars, journal club; 
committee meetings 
University of Utah Medical Center 
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drug manufacturing and extemporaneous compounding for 
drug study protocols 
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PROFESSIONAL EXPERIENCE (Continued) 
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University of Utah College of Pharmacy 
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Duties: preparation, isolation and purification of isoleucine-
transfer RNA from various strains of Escherichia coll 
Department of Pharmacy Services 
University of Utah Medical Center 
Salt Lake City, UT - July 1979-June 1980 
Pharmacy Intern 
Duties: dispensing and counseling function with outpatients; 
medication counseling/drug histories from inpatients; 
filling and checking of unit-dose medication carts; 
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Food and Dairy Laboratory 
San Francisco, CA - June 1978-August 1978 
Laboratory Technician 
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American Society of Hospital Pharmacists 
Utah Society of Hospital Pharmacists 
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Student Representative to the Curriculum Committee 
University of Utah College of Pharmacy, 1979-1980, 1981-1982 
Reviewer, American Hospital Formulary Service, 1981 
Student Advisory Committee 
University of Utah College of Pharmacy, 1981-1982 
College Council, University of Utah, 1981-1982 
TEACHING EXPERIENCE 
Teaching Fellow - Department of Pharmacy Practice 
University of Utah College of Pharmacy - Clinical Toxicology 
for undergraduate pharmacy students 
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TEACHING EXPERIENCE (continued) 
Teaching Assistant - Department of Pharmacy Practice, University 
of Utah, for Adult Internal Medicine, Drug Information, Peri-
natology (OB/GYN), Pediatrics, Ambulatory Peds/Geriatrics Clerk-
ships for fifth year pharmacy students 
Teaching Assistant/Lab Instructor - Department of Chemistry, 
San Francisco State University, for freshmen chemistry students 
Student Assistant - Department of Microbiology, San Francisco 
State University, for junior and senior microbiology students 
RESEARCH IN PROGRESS 
Evaluation of an Automated Intragastric pH Titration System in 
Critically III Patients 
Investigators: MP Quan, Pharra.D. Candidate; J Russo, Jr., Pharm.D. 
KR Larsen, Ph.D.; FG Moody, M.D. 
Determination of the Kinetics of Cefoxitin in Patients Undergoing 
Peritoneal Dialysis 
Investigators: MIB Thompson, Pharm.D.; MC Gregory, M.D.; 
J Russo, Jr., Pharm.D.; ME Russo, Pharm.D.; 
MP Quan, Pharm.D. Candidate 
A Comparison Study of the Safety and Efficacy of Various Topical 
OTC Preparations Used in the Treatment of Diaper Dermatitis 
Investigators: ML Ashley, P.N.P.; MP Quan, Pharm.D. Candidate; 
T Metcalf, M.D. 
COMPLETED RESEARCH 
Evaluation of an UV Irradiation System for the Treatment of Waste-
water 
Investigator: MP Quan, M.A. Microbiology Candidate 
Comparison of Various TLC Visualization Methods for Amanita 
phalloides toxin 
Investigator: MP Quan 
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Studies. In-house publication - San Francisco State 
University, 1978 
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3(4):5-6 
Quan MP and Gross ME: Ketoconazole: A new oral antifungal agent 
is admitted to the formulary. Drugs in Patient Care 1981; 
5(1):1-2 
MANUSCRIPTS IN PROGRESS 
Veltri JC and Quan MP: Hydrocarbon toxicity and management. In: 
Clinical Toxicology, Vol. 2 (VA Skoutakis, Ed.) Williams and 
Wilkins 
INVITED LECTURES AND PRESENTATIONS 
"Management of Digoxin Toxicity" presented in Advanced Toxicology 
class to first year Pharm.D. candidates, University of Utah, 
May 1982 
"Chronic Renal Failure" presented in Diseases and Drug Therapy 
class to fourth year pharmacy students, University of Utah, 
March 1982 
"Acute Renal Failure" presented in Diseases and Drug Therapy class 
to fourth year pharmacy students, University of Utah, February 
1982 
"Ketoconazole: Therapeutic Considerations" presented in Dermatology 
Clinical Conference to the Department of Dermatology, University 
of Utah Medical Center, January 1982 
"Stress Erosion Prophylaxis" presented in Surgical Research Con-
ference to the Department of Surgery, University of Utah Medical 
Center, January 1982 
"The Hemolytic Anemias" presented in Advanced Pharmacotherapeutics 
to first year Pharm.D. candidates, University of Utah, January 
1982 
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INVITED LECTURES AMD PRESENTATIONS (continued) 
"Amantadine in the Prophylaxis and Management of Influenzae" 
presented in Infectious Disease Grand Rounds, University of 
Utah Medical Center, October 1981 
"Urinary Tract Infections" presented in Advanced Pharmacothera-
peutics to first year Pharm.D. candidates, University of Utah, 
October 1981 
"Aminoglycoside Nephrotoxicity" presented to the Departments of 
Nephrology, University of Utah Medical Center and Salt Lake 
City V.A. Medical Center, September 1981 
"I.V. Metronidazole Kinetics" presented to the Pharmacy and 
Therapeutics Committee, University of Utah Medical Center, 
June 1981 
"Treatment of Fever of Unknown Origin in the Neutropenic Patient" 
presented to the Medical Staff-Pediatrics Unit, University of 
Utah Medical Center, April 1981 
"Use of Anti-Platelet Agents in the Treatment of Transient 
Ischemic Attacks" presented to the Medical Staff-Geriatric 
Evaluation and Treatment Unit, Salt Lake City, V.A. Medical 
Center, February 1981 
"Rational Use of Topical Preparations" presented to the Medical 
Staff-Ambulatory Pediatric Clinic, University of Utah Medi-
cal C6X11GIT • January 1981 
"Lithium for the Treatment of Aggression" presented to the 
Medical Staff-Psychiatric Unit, Salt Lake City V.A. Medical 
Center, November 1980 
"Techniques of Obtaining and Using a Medication History" pre-
sented to the Nursing Staff and Other Health Professions-
Geriatric Health Screening Center, Salt Lake City, October 
1980 
"Lithium in the Treatment of Manic-Depressive Illness" presented 
to the Nursing Staff and Medical Students-Psychiatric Unit, 
S Silt City V.A. Medical Center, October 1980 
"Psychiatric Medications" presented to Inpatients in the Psychi-
atric Unit, Salt Lake City V.A. Medical Center, September 1980 
"Review of the Benzodiazepines" presented to the Medical Staff-
Psychiatric Unit, Salt Lake City V.A. Medical Center, 
September 1980 
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INVITED LECTURES AND PRESENTATIONS (Continued) 
"Agents Used in the Treatment of Constipation and Diarrhea" pre-
sented to the Medical Staff-Adult Medicine Unit, University, 
of Utah Medical Center, September 1980 
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Grace P. Swinyard Memorial Scholarship Award from the University 
of Utah College of Pharmacy, 1979-1980, 1980-1981 
Rho Chi Honor Society, initiated 1980 
Phi Kappa Phi Honor Society, initiated 1979 
National Merit Certification of Commendation, 1973-1974 
